JPMorgan Chase & Co. Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price

Key Points

• JPMorgan raised Vera Therapeutics’ price target to $83 from $76 and maintained an “overweight” rating, implying 136.8% upside from the stock’s prior close.
• Analyst sentiment remains positive overall, with a MarketBeat consensus rating of “Moderate Buy” and an average price target of $80.15, though targets range from $34 to $90.
• VERA traded near $35, while the company reported quarterly EPS of -$1.52, beating estimates by $0.06. CEO Marshall Fordyce also sold 18,500 shares under a pre-arranged trading plan.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) had its target price upped by investment analysts at JPMorgan Chase & Co. from $76.00 to $83.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target indicates a potential upside of 136.80% from the stock's previous close.

Other analysts also recently issued research reports about the company. Guggenheim upped their target price on Vera Therapeutics from $56.00 to $76.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Wedbush reaffirmed a "neutral" rating and set a $34.00 price objective on shares of Vera Therapeutics in a research note on Monday, August 17th. The Goldman Sachs Group reiterated a "buy" rating and issued a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. William Blair reissued an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, HC Wainwright cut their price objective on shares of Vera Therapeutics from $125.00 to $90.00 and set a "buy" rating for the company in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Vera Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $80.15.

Vera Therapeutics Stock Performance

VERA stock traded down $0.84 during midday trading on Tuesday, reaching $35.05. The stock had a trading volume of 254,793 shares, compared to its average volume of 1,498,341. The firm has a fifty day simple moving average of $35.72 and a two-hundred day simple moving average of $37.37. Vera Therapeutics has a 52-week low of $22.72 and a 52-week high of $56.05. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. The stock has a market cap of $2.53 billion, a PE ratio of -5.98 and a beta of 0.96.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating analysts' consensus estimates of ($1.58) by $0.06. During the same period last year, the business earned ($1.20) earnings per share. As a group, equities research analysts anticipate that Vera Therapeutics will post -6.45 EPS for the current year.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $35.12, for a total value of $649,720.00. Following the completion of the sale, the chief executive officer directly owned 235,244 shares in the company, valued at $8,261,769.28. This represents a 7.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,250 shares of company stock worth $3,307,800 in the last three months. 15.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Los Angeles Capital Management LLC acquired a new stake in shares of Vera Therapeutics in the fourth quarter valued at approximately $46,000. Quantbot Technologies LP purchased a new stake in Vera Therapeutics in the 2nd quarter valued at $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Vera Therapeutics in the 4th quarter valued at $71,000. Nykredit A S acquired a new stake in shares of Vera Therapeutics in the 2nd quarter worth $97,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company's stock worth $99,000 after acquiring an additional 2,757 shares during the period. 99.21% of the stock is owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.